デフォルト表紙
市場調査レポート
商品コード
1007184

抗うつ薬の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)

Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.07円
抗うつ薬の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)
出版日: 2021年05月20日
発行: IMARC Services Private Limited
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の鬱病治療薬の市場規模は2020年に127億米ドルに達しました。うつ病は、前向きな感情の欠如、絶え間ない気分の落ち込み、および多数の認知的、身体的、行動的、感情的な症状を特徴とする精神障害です。症状を特定し、患者の病歴を確認することで診断されます。次に、脳内のセロトニンなどの神経伝達物質の機能のバランスを取り、患者の気分や感情を制御する鬱病治療薬を使用して治療されます。これらの薬は、不安、季節性情動障害、気分変調の兆候を和らげるのに役立ちます。

世界保健機関(WHO)によると、うつ病は障害の主な原因の1つであり、世界中で2億6,400万人以上に影響を与えています。社交不安やうつ病などの精神障害の蔓延の増加は、鬱病治療薬市場の成長を促進する主要な要因の1つとなっています。これとは別に、新型コロナウイルス感染症(COVID-19)の症例の急増に伴い、人々にはかなりの程度の恐怖、心配、懸念があります。さらに、各国の政府が完全な封鎖を課し、社会的距離基準の採用を促進しているため、人口のかなりの部分の日常生活が変化し、それが個人の精神的健康に悪影響を及ぼしています。この傾向は、鬱病治療薬の売上を押し上げるもう1つの主要な成長誘発要因として浮上しています。さらに、副作用が最小限で長期的な結果が得られる鬱病治療薬を開発するための新しい技術の出現は、新薬の受け入れの増加と合わせて、今後数年間で市場成長を後押しすると予想されています。世界の鬱病治療薬市場は、2021年から2026年までの予測期間中に約3%のCAGRで成長すると予想されています。

当レポートは、世界の鬱病治療薬市場について調査しており、業界動向、市場予測、薬物クラス・障害タイプ・薬の種類・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の鬱病治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 薬物クラス別の市場セグメンテーション
  • 障害タイプ別の市場セグメンテーション
  • 薬の種類別の市場セグメンテーション
  • 流通チャネル別の市場セグメンテーション
  • 地域別の市場セグメンテーション

第6章 薬物クラス別の市場セグメンテーション

  • 非定型抗精神病薬
  • セロトニン-ノルエピネフリン再取り込み阻害薬(SNRI)
  • 選択的セロトニン再取り込み阻害薬(SSRI)
  • 中枢神経系(CNS)覚醒剤
  • 三環系鬱病治療薬
  • モノアミンオキシダーゼ阻害剤
  • その他

第7章 障害タイプ別の市場セグメンテーション

  • 大鬱病性障害
  • 強迫性障害
  • 全般性不安障害
  • パニック障害
  • その他

第8章 薬の種類別市場セグメンテーション

  • ジェネリック医薬品
  • ブランド薬

第9章 流通チャネル別の市場セグメンテーション

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第10章 地域別の市場セグメンテーション

  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • ラテンアメリカ

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Otsuka Pharmaceutical
    • Pfizer
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis
    • Bristol-Myers Squibb
    • GlaxoSmithKline
    • Takeda Pharmaceutical Company
    • Allergan
    • Johnson & Johnson
    • Zhejiang NHU Company Ltd
    • Sebela Pharmaceuticals
図表

List of Figures

  • Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Depression Drugs Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2020
  • Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2020
  • Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2020
  • Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2020
  • Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2020
  • Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 9: Global: Depression Drugs Industry: SWOT Analysis
  • Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
  • Figure 11: Global: Depression Drugs Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulant) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulant) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2015 & 2020
  • Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2021-2026
  • Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million US$), 2015 & 2020
  • Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2021-2026
  • Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million US$), 2015 & 2020
  • Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2021-2026
  • Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million US$), 2015 & 2020
  • Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2021-2026
  • Figure 48: North America: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 50: Europe: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026

List of Tables

  • Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
  • Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million US$), 2021-2026
  • Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
  • Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 7: Global: Depression Drugs Market Structure
  • Table 8: Global: Depression Drugs Market: Key Players
目次
Product Code: SR1020C270_Report

The global depression drugs market reached a value of US$ 12.7 Billion in 2020. Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Apart from this, with the surge in the cases of the coronavirus disease (COVID-19), there is a considerable degree of fear, worry and concern in the population. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years. Looking forward, the global depression drugs market is expected to grow at a CAGR of around 3% during the forecast period (2021-2026).

IMARC Group's latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global depression drugs market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug class, disorder type, drug type, and distribution channel.

Report Coverage:

  • Historical, Current and Future Market Trends

Market Breakup by Drug Class:

  • Atypical Antipsychotics
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Central Nervous System (CNS) Stimulants
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Others

Market Breakup by Disorder Type:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

Market Breakup by Drug Type:

  • Generic Drugs
  • Branded Drugs

Market Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Competitive Landscape:

  • The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Depression Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Class
  • 5.5 Market Breakup by Disorder Type
  • 5.6 Market Breakup by Drug Type
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Atypical Antipsychotics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Central Nervous System (CNS) Stimulants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tricyclic Antidepressants
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Monoamine Oxidase Inhibitors
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disorder Type

  • 7.1 Major Depressive Disorder
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Obsessive-Compulsive Disorder
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Generalized Anxiety Disorder
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panic Disorder
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Generic Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Branded Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Otsuka Pharmaceutical
    • 15.3.2 Pfizer
    • 15.3.3 Eli Lilly and Company
    • 15.3.4 AstraZeneca
    • 15.3.5 Novartis
    • 15.3.6 Bristol-Myers Squibb
    • 15.3.7 GlaxoSmithKline
    • 15.3.8 Takeda Pharmaceutical Company
    • 15.3.9 Allergan
    • 15.3.10 Johnson & Johnson
    • 15.3.11 Zhejiang NHU Company Ltd
    • 15.3.12 Sebela Pharmaceuticals